Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications

已完结 10 由钱钱发布于 2025/9/19 11:47:40

DOI:10.1016/j.cllc.2022.11.004
作者：Byoung Chul Cho , Allison Simi , Joshua Sabari , Smruthi Vijayaraghavan , Sheri Moores , Alexander Spira
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Substantial therapeutic advancements have been made in identifying and treating activating mutations in advanced non-small cell lung cancer (NSCLC); however, resistance to epidermal growth f

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileySynthetic microbial communities: Sandbox and blueprint for soil health enhancement